Page 198 - IJB-10-3

International Journal of Bioprinting Bioprinted tissue-on-a-chip in drug screening

representative structures with the help of 3D bioprinting 3. Advancing cancer therapy. Nat Cancer. 2021;2(3):245-246.
technologies and then dynamically cultured through doi: 10.1038/s43018-021-00192-x
microfluidic technologies. The combination of these two 4. Bains W. Failure rate in drug discovery and development:
technologies has the potential to eliminate biological will we ever get any better? Drug Discov World. 2004;5.
limitations and produce more standardized and persuasive 5. Imamura Y, Mukohara T, Shimono Y, et al. Comparison of
results for drug screening. Furthermore, integrated chips 2D- and 3D-culture models as drug-testing platforms in
will significantly influence personalized medicine and drug breast cancer. Oncol Rep. 2015;33(4):1837-1843.
administration. In the future, tissue chips can be universal, doi: 10.3892/or.2015.3767
providing a model that satisfies different patients and even
different types of cancers. 6. Jensen C, Teng Y. Is it time to start transitioning from 2D to
3D cell culture? Front Mol Biosci. 2020;7:33.
Acknowledgments doi: 10.3389/fmolb.2020.00033
7. de Jong M, Maina T. Of mice and humans: are they the
None. same?--Implications in cancer translational research. J Nucl
Med. 2010;51(4):501-504.
Funding doi: 10.2967/jnumed.109.065706

This work was supported by the National Key 8. Mak IW, Evaniew N, Ghert M. Lost in translation: animal
R&D Program of China (2018AAA0100300) and models and clinical trials in cancer treatment. Am J Transl
the Fundamental Research Funds for the Central Res. 2014;6(2):114-118.
Universities (DUT22YG238). 9. Dey M, Ozbolat IT. 3D bioprinting of cells, tissues and
organs. Sci Rep. 2020;10:14023.
Conflict of interest doi: 10.1038/s41598-020-70086-y
The authors declare no conflicts of interest. 10. Staros R, Michalak A, Rusinek K, Mucha K, Pojda Z,
Zagożdżon R. Perspectives for 3D-bioprinting in modeling of
Author contributions tumor immune evasion. Cancers (Basel). 2022;14(13):3126.
doi: 10.3390/cancers14133126
Conceptualization: Hangyu Zhang, Jianing Li
Funding acquisition: Hangyu Zhang, Shen Li 11. Xie F, Sun L, Pang Y, et al. Three-dimensional bio-printing of
Supervision: Hangyu Zhang primary human hepatocellular carcinoma for personalized
Writing – original draft: Jianing Li medicine. Biomaterials. 2021;265:120416.
doi: 10.1016/j.biomaterials.2020.120416
Writing – review & editing: Na Li, Bo Liu, Shen Li,
Hangyu Zhang 12. Jia X, Yang X, Luo G, Liang Q. Recent progress of microfluidic
technology for pharmaceutical analysis. J Pharm Biomed
Ethics approval and consent to participate Anal. 2022;209:114534.
doi: 10.1016/j.jpba.2021.114534
Not applicable.
13. Yu F, Choudhury D. Microfluidic bioprinting for organ-on-
Consent for publication a-chip models. Drug Discov Today. 2019;24(6):1248-1257.
doi: 10.1016/j.drudis.2019.03.025
Not applicable. 14. Tiwari AP, Thorat ND, Pricl S, Patil RM, Rohiwal S, Townley
H. Bioink: a 3D-bioprinting tool for anticancer drug
Availability of data discovery and cancer management. Drug Discov Today.

Not applicable. 2021;26(7):1574-1590.
doi: 10.1016/j.drudis.2021.03.010
References 15. Ji S, Guvendiren M. Recent advances in bioink design for 3D
bioprinting of tissues and organs. Front Bioeng Biotechnol.
1. Dawood AA, Yousif WI. The main reasons why cancer is 2017;5:23.
so difficult to treatment. AJOAIMS. Philadelphia: Elsevier; doi: 10.3389/fbioe.2017.00023
2020;2(2):20-22. 16. Nejman D, Livyatan I, Fuks G, et al. The human tumor
2. DeBerardinis RJ. Tumor microenvironment, metabolism, microbiome is composed of tumor type-specific intracellular
and immunotherapy. N Engl J Med. 2020;382(9):869-871. bacteria. Science. 2020;368(6494):973-980.
doi: 10.1056/NEJMcibr1914890 doi: 10.1126/science.aay9189

Volume 10 Issue 3 (2024) 190 doi: 10.36922/ijb.1951